Advances of antibody-drug conjugate in the therapy of metastatic breast cancer

VernacularTitle:抗体药物偶联物在转移性乳腺癌治疗中的研究进展
Author: Ying WANG ¹ ; Nan LIU ; Bing GUO
Author Information

1. 中国科学院合肥肿瘤医院乳腺肿瘤中心，合肥　230031
Keywords: Breast neoplasms; Neoplasm metastasis; Molecular targeted therapy; Antibody-drug conjugate
From: Journal of International Oncology 2024;51(6):364-369
CountryChina
Language:Chinese
Abstract: Antibody-drug conjugate (ADC) couplings enable precise tumor targeted chemotherapy by combining cytotoxic drugs with antibodies against tumor cell targets via a linker. Trastuzumab emtansine and trastuzumab deruxtecan targeting human epidermal growth factor receptor (HER) 2 are effective and have been approved as the standard second-line treatment for HER2-positive metastatic breast cancer. Sacituzumab govitecan targeting trophoblast cell surface antigen-2 has achieved remarkable efficacy in the treatment of metastatic triple-negative breast cancer. Other ADC that targeting Nectin-4, mesothelin, LIV-1, receptor tyrosine kinase-like orphan receptor, HER3, and other targets have reasonable efficacy and broad prospects. Further discussion on the research progress of ADC in the treatment of metastatic breast cancer can provide ideas for the application and development of ADC.